Ganglioside M2 (GM2) (GM2)

Ganglioside M2 (GM2) is a sialic acid-containing glycosphingolipid primarily located in the outer leaflet of plasma membranes, particularly within the central nervous system (PubChem CID 9835421). It plays a vital role in cell-cell recognition, signal transduction, and the modulation of membrane-bound receptors and ion channels (NCBI Bookshelf, NBK1218). In healthy cells, GM2 is degraded in lysosomes by the enzyme beta-hexosaminidase A; however, mutations in the HEXA gene lead to the accumulation of GM2, resulting in Tay-Sachs disease, a severe neurodegenerative disorder (PubMed PMID: 11586470). Furthermore, GM2 is classified as a tumor-associated carbohydrate antigen (TACA) because it is highly expressed on the surface of various cancers, including melanoma, neuroblastoma, and certain sarcomas, while its expression in normal tissues is highly restricted (PubMed PMID: 22510536). This differential expression makes GM2 a significant target for cancer immunotherapies, such as the GM2-KLH vaccine and various monoclonal antibodies designed to trigger immune-mediated destruction of tumor cells. In the context of lysosomal storage diseases, therapeutic strategies focus on substrate reduction therapy (SRT) using drugs like miglustat to decrease the synthesis of GM2 and mitigate its toxic accumulation (DrugBank DB00519).

Other names

GM2 gangliosideMonosialotetrahexosylgangliosideGalNAc-Gal(NeuAc)-Glc-CerGanglioside G2

Active immunotherapy (vaccine-induced production of anti-GM2 antibodies); Substrate reduction therapy (inhibition of glucosylceramide synthase to reduce GM2 synthesis); Passive immunotherapy (monoclonal antibody binding to tumor-associated GM2).